Daniela Farkas1, A A Roger Thompson2, Aneel R Bhagwani1, Schuyler Hultman1, Hyun Ji1, Naveen Kotha1, Grant Farr1, Nadine D Arnold2, Adam Braithwaite2, Helen Casbolt2, Jennifer E Cole3, Ian Sabroe2, Claudia Monaco3, Carlyne D Cool4, Elena A Goncharova5,6, Allan Lawrie2, Laszlo Farkas1. 1. 1 Division of Pulmonary Disease and Critical Care Medicine, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia. 2. 2 Department of Infection, Immunity & Cardiovascular Disease, Faculty of Medicine, Dentistry & Health, University of Sheffield, Sheffield, United Kingdom. 3. 3 Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom. 4. 4 Department of Pathology, University of Colorado Denver, Denver, Colorado; and. 5. 5 Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, and. 6. 6 Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
RATIONALE: Pulmonary arterial hypertension (PAH) is characterized by vascular cell proliferation and endothelial cell apoptosis. TLR3 (Toll-like receptor 3) is a receptor for double-stranded RNA and has been recently implicated in vascular protection. OBJECTIVES: To study the expression and role of TLR3 in PAH and to determine whether a TLR3 agonist reduces pulmonary hypertension in preclinical models. METHODS: Lung tissue and endothelial cells from patients with PAH were investigated by polymerase chain reaction, immunofluorescence, and apoptosis assays. TLR3-/- and TLR3+/+ mice were exposed to chronic hypoxia and SU5416. Chronic hypoxia or chronic hypoxia/SU5416 rats were treated with the TLR3 agonist polyinosinic/polycytidylic acid (Poly[I:C]). MEASUREMENTS AND MAIN RESULTS: TLR3 expression was reduced in PAH patient lung tissue and endothelial cells, and TLR3-/- mice exhibited more severe pulmonary hypertension following exposure to chronic hypoxia/SU5416. TLR3 knockdown promoted double-stranded RNA signaling via other intracellular RNA receptors in endothelial cells. This was associated with greater susceptibility to apoptosis, a known driver of pulmonary vascular remodeling. Poly(I:C) increased TLR3 expression via IL-10 in rat endothelial cells. In vivo, high-dose Poly(I:C) reduced pulmonary hypertension in both rat models in proof-of-principle experiments. In addition, Poly(I:C) also reduced right ventricular failure in established pulmonary hypertension. CONCLUSIONS: Our work identifies a novel role for TLR3 in PAH based on the findings that reduced expression of TLR3 contributes to endothelial apoptosis and pulmonary vascular remodeling.
RATIONALE: Pulmonary arterial hypertension (PAH) is characterized by vascular cell proliferation and endothelial cell apoptosis. TLR3 (Toll-like receptor 3) is a receptor for double-stranded RNA and has been recently implicated in vascular protection. OBJECTIVES: To study the expression and role of TLR3 in PAH and to determine whether a TLR3 agonist reduces pulmonary hypertension in preclinical models. METHODS: Lung tissue and endothelial cells from patients with PAH were investigated by polymerase chain reaction, immunofluorescence, and apoptosis assays. TLR3-/- and TLR3+/+ mice were exposed to chronic hypoxia and SU5416. Chronic hypoxia or chronic hypoxia/SU5416rats were treated with the TLR3 agonist polyinosinic/polycytidylic acid (Poly[I:C]). MEASUREMENTS AND MAIN RESULTS:TLR3 expression was reduced in PAH patient lung tissue and endothelial cells, and TLR3-/- mice exhibited more severe pulmonary hypertension following exposure to chronic hypoxia/SU5416. TLR3 knockdown promoted double-stranded RNA signaling via other intracellular RNA receptors in endothelial cells. This was associated with greater susceptibility to apoptosis, a known driver of pulmonary vascular remodeling. Poly(I:C) increased TLR3 expression via IL-10 in rat endothelial cells. In vivo, high-dose Poly(I:C) reduced pulmonary hypertension in both rat models in proof-of-principle experiments. In addition, Poly(I:C) also reduced right ventricular failure in established pulmonary hypertension. CONCLUSIONS: Our work identifies a novel role for TLR3 in PAH based on the findings that reduced expression of TLR3 contributes to endothelial apoptosis and pulmonary vascular remodeling.
Authors: Ann M Reynolds; Wei Xia; Mark D Holmes; Sandra J Hodge; Sergei Danilov; David T Curiel; Nicholas W Morrell; Paul N Reynolds Journal: Am J Physiol Lung Cell Mol Physiol Date: 2007-02-02 Impact factor: 5.464
Authors: L Taraseviciene-Stewart; Y Kasahara; L Alger; P Hirth; G Mc Mahon ; J Waltenberger; N F Voelkel; R M Tuder Journal: FASEB J Date: 2001-02 Impact factor: 5.191
Authors: Carl Atkinson; Susan Stewart; Paul D Upton; Rajiv Machado; Jennifer R Thomson; Richard C Trembath; Nicholas W Morrell Journal: Circulation Date: 2002-04-09 Impact factor: 29.690
Authors: Elaine Soon; Alan M Holmes; Carmen M Treacy; Natalie J Doughty; Laura Southgate; Rajiv D Machado; Richard C Trembath; Simon Jennings; Lucy Barker; Paul Nicklin; Christoph Walker; David C Budd; Joanna Pepke-Zaba; Nicholas W Morrell Journal: Circulation Date: 2010-08-16 Impact factor: 29.690
Authors: Karen A Cavassani; Makoto Ishii; Haitao Wen; Matthew A Schaller; Pamela M Lincoln; Nicholas W Lukacs; Cory M Hogaboam; Steven L Kunkel Journal: J Exp Med Date: 2008-10-06 Impact factor: 14.307
Authors: Daniela Farkas; Donatas Kraskauskas; Jennifer I Drake; Aysar A Alhussaini; Vita Kraskauskiene; Harm J Bogaard; Carlyne D Cool; Norbert F Voelkel; Laszlo Farkas Journal: PLoS One Date: 2014-02-24 Impact factor: 3.240
Authors: Elena A Goncharova; Stephen Y Chan; Corey E Ventetuolo; Norbert Weissmann; Ralph T Schermuly; Christopher J Mullin; Mark T Gladwin Journal: Am J Respir Crit Care Med Date: 2020-07-01 Impact factor: 21.405